The limited success in understanding the pathophysiology of major depression may result from excessive focus on the dysfunctioning of neurons, as compared with other types of brain cells. Therefore, we examined the role of dynamic alterations in microglia activation status in the development of chronic unpredictable stress (CUS)-induced depressive-like condition in rodents. We report that following an initial period (2-3 days) of stress-induced microglial proliferation and activation, some microglia underwent apoptosis, leading to reductions in their numbers within the hippocampus, but not in other brain regions, following 5 weeks of CUS exposure. At that time, microglia displayed reduced expression of activation markers as well as dystrophic morphology. Blockade of the initial stress-induced microglial activation by minocycline or by transgenic interleukin-1 receptor antagonist overexpression rescued the subsequent microglial apoptosis and decline, as well as the CUS-induced depressive-like behavior and suppressed neurogenesis. Similarly, the antidepressant drug imipramine blocked the initial stress-induced microglial activation as well as the CUS-induced microglial decline and depressive-like behavior. Treatment of CUS-exposed mice with either endotoxin, macrophage colony-stimulating factor or granulocyte-macrophage colony-stimulating factor, all of which stimulated hippocampal microglial proliferation, partially or completely reversed the depressive-like behavior and dramatically increased hippocampal neurogenesis, whereas treatment with imipramine or minocycline had minimal or no anti-depressive effects, respectively, in these mice. These findings provide direct causal evidence that disturbances in microglial functioning has an etiological role in chronic stress-induced depression, suggesting that microglia stimulators could serve as fast-acting antidepressants in some forms of depressive and stress-related conditions.
Despite impressive progress in understanding the molecular, cellular and circuit-level correlates of major depression, the biological mechanisms that causally underlie this disorder are still unclear, hindering the development of effective preventive and therapeutic procedures. One possible reason for this situation is that almost all research in this area focuses on the involvement of abnormalities in neuronal functioning, [1] [2] [3] whereas the involvement of non-neuronal brain cells has not been thoroughly examined. Over the past decade, it has been suggested that glial cells, particularly astrocytes, may be also involved in the pathophysiology of depression; [4] [5] [6] however, almost no research has focused on the role of microglia. Microglia, which comprise roughly 10% of brain cells, are the resident innate immune cells in the brain, and therefore their activation has a major role in brain infection, injury and neurodegenerative diseases. In addition, they are highly motile in their resting/quiescent state and actively participate in synaptic changes, micro-damage repair and neurogenesis. 7, 8 Several circumstantial lines of evidence suggest that microglia may also have a role in depression, including the findings that: (1) Microglial status is altered in some depressed patients, particularly in relation to suicide; 9, 10 (2) Most neurological diseases are characterized by a high incidence of depression 11 along with marked microglial alterations; 8 (3) Pro-inflammatory cytokines, whose main cellular source in the brain is microglia, are elevated in the cerebro-spinal fluid of some depressed patients; 12, 13 (4) A substantial percentage of cancer or hepatitis C patients who receive immunotherapy with interferon-a, which activates microglia, develop major depression; 14 (5) Healthy volunteers who are experimentally exposed to microglial stimulators, particularly endotoxin (lipopolysaccharide (LPS)), develop depressed mood; 15, 16 (6) Experimental animals exposed to immune challenges that activate microglia display depressive-like symptoms that can be reversed by chronic treatment with antidepressants, as well as by cytokine antagonists or manipulations of cytokine genes; [17] [18] [19] (7) Antidepressant drugs can modulate microglial activities; 20, 21 and (8) Microglia are important regulators of hippocampal neurogenesis, [22] [23] [24] [25] which in turn modulates the development of depression 26 and constitute a major target for antidepressant drugs. [27] [28] [29] Microglial activation and brain inflammatory cytokines have also been implicated in mediating the effects of stress, 30 which both in humans and in animal models has been implicated as a major trigger for depression. [31] [32] [33] [34] Specifically, exposure to acute stressful conditions can directly induce microglial activation, 35, 36 and the microglial inhibitor minocycline has been reported to block stress-induced hypothalamic interleukin (IL)-1 secretion. 37, 38 stress for 4-21 days induces microglia proliferation and activation in several stress-responsive brain regions. [39] [40] [41] In addition, the depressive and neurogenesis-suppressive effects of chronic stress in rodents were found to be mediated by the microglial-derived cytokine IL-1. 30, 42, 43 Together, these findings suggest that stressinduced microglial alterations are critically involved in the development of depression and neurogenesis suppression. In the present study, we tested this hypothesis by examining whether there are dynamic changes in microglia number and activation status during the development of chronic stressinduced depressive-like condition in rodents and whether any such changes have a causal role.
MATERIALS AND METHODS Subjects
Subjects were 2-4-month-old male mice or rats. Animals were housed 2-3 per cage in temperature (23±2 1C) controlled rooms with standard rodent chow and water available ad libitum (unless mentioned otherwise). The behavioral experiments were conducted during the first half of the dark phase of a reversed 12 h light/dark cycle. All experiments were approved by the Hebrew University of Jerusalem, Israel or the University of Colorado Committees for Animal Care and Use. Most experiments were conducted in heterozygous mice expressing transgenic enhanced green fluorescent protein in conjunction with the CX3C (fractalkine) receptor type 1 (CX3CR1), which in the brain is expressed exclusively by resident microglia 44 along with their C57BL wild-type (WT) littermates. In experiments on the IL-1 system, we used mice with transgenic overexpression of IL-1 receptor antagonist (IL-1raTG) under the control of the glial fibrillary acidic protein promoter and their C57BL/6 Â CBA WT controls. These mice were shown to secrete hIL-1ra only within their central nervous system and to be completely unresponsive to exogenous or endogenous IL-1b. 45, 46 In studies on rats, we used adult male Sprague-Dawley rats (weighing 260-300 g at the beginning of the experiment; Harlan Laboratories, Indianapolis, IN, USA).
Stress exposure paradigms
To induce chronic stress in mice, the chronic unpredictable stress (CUS) paradigm was used, consisting of daily exposure to two of the following stressors in a random order over a 5-week period: cage shaking for 1 h, lights on during the entire night (12 h), placement in 4 1C cold room for 1 h, mild restraint (in small cages) for 2 h, 451 cage tilt for 14 h, lights-off for 3 h during the daylight phase, wet cage for 14 h, flashing (stroboscopic) light for 6 h, noise in the room for 3 h, and water deprivation for 12 h during the dark period. Shorter periods of unpredictable stress (US) included various combinations of 2-3 of the above-mentioned stressors over a period of 2-4 days. To induce chronic stress in rats, the chronic mild stress (CMS) paradigm was used over a 5-week period, consisting of daily exposure to two of the following stressors in a random order: food deprivation or water deprivation for 12 h during the dark phase of the circadian cycle, lights on during the entire night (12 h), soaked cage for 14 h, 451 cage tilt for 3 h, flashing light for 1 h, and radio noise in the room for 4 h. Shorter periods of mild stress exposure included various combinations of 2-3 of the abovementioned stressors over a period of 24 or 48 h.
Behavioral measurements
Sucrose preference. Following baseline adaptation to sucrose for several days, animals were presented in the beginning of the dark circadian phase with two graduated drinking tubes, one containing tap water and the other 2% sucrose solution for 3 h. Sucrose preference was calculated as the percentage of sucrose consumption out of the total drinking volume.
Social exploration. Each subject was placed in an observation cage and allowed to habituate to the cage for 15 min, following which a male juvenile was placed in the cage. Social exploration, defined as the time of near contact between the nose of the subject and the juvenile conspecific, was then recorded for 2 min, using computerized in-house software.
The open field test. In the beginning of this test, each mouse was placed in the corner of a white 80 Â 80 cm 2 plastic arena with 50-cm-high walls. The time spent and distance traveled in the center of the box (60 cm 2 area) vs the outside zone (the rest of the box area) was measured over a 3-min period. Behavior was analyzed using the EthoVision XT video tracking system and software (Noldus, The Netherlands).
The Porsolt forced swim test. Mice were placed in a 20-cm diameter glass cylinder filled to 10 cm with 21 1C water, and their behavior was analyzed for 5 min. The time spent in immobility, defined as the absence of all movement except motions required to maintain the animal's head above the water, and the latency to first immobility episode were recorded using an in-house computerized software.
Pharmacological treatments
The tricyclic antidepressant drug imipramine (Sigma, Rehovot, Israel) was administered via drinking water at a dose of 20 mg kg À 1 day À 1 . Minocycline (Sigma, Israel) was administrated via drinking water at a dose of 40 mg kg À 1 day À 1 (this dose regimen has been previously found to be effective in counteracting chronic stress-induced microglial alterations and behavioral changes). 47, 48 Because animals were housed 2-3/cage, these doses of imipramine and minocycline represent the averaged, rather than the exact individual doses consumed by each animal in the cage. LPS (from Escherichia coli, serotype 0111: B4, Sigma, Israel) was injected intrapritoneally (i.p.) at a dose of 100 mg kg À 1 (this dose was used because we as well as others have previously found that it produces behavioral symptoms that can be attenuated by anti-depressive treatment). 17, 18 Mouse macrophage colony-stimulating factor (M-CSF; Prospec, Ness-Ziona, Israel) was injected i.p. daily at a dose of 100 mg kg À 1 (this dose was used based on a previous study demonstrating its effectiveness in microglia stimulation 49 and on a preliminary experiment in our lab, demonstrating that it induces marked microglial proliferation in chronically stressed mice). Mouse granulocytes-macrophage colony-stimulating factor (GM-CSF; Prospec, Israel) was injected i.p. three times a week over a 2-week period at a dose of 100 mg kg À 1 (this dose was used based on previous studies demonstrating its effectiveness in microglia stimulation 50, 51 and on a preliminary experiment in our lab, demonstrating that it induces marked microglial proliferation in chronically stressed mice).
Molecular and biochemical measurements
Real-time reverse transcriptase-PCR. Total RNA was isolated from the whole hippocampus of stress-exposed and control rats, utilizing a standard method of phenol:chloroform extraction. 52 For detailed descriptions of RNA isolation, cDNA synthesis and PCR amplification protocols, refer to previous publication. 53 cDNA sequences were obtained from Genbank at the National Center for Biotechnology Information (NCBI; www.ncbi. nlm.nih.gov). Primer sequences were designed using the Operon Oligo Analysis Tool (http://www.operon.com/technical/toolkit.aspx) and tested for sequence specificity using the Basic Local Alignment Search Tool at NCBI. 54 Primers were obtained from Invitrogen (Grand Island, NY, USA). Primer specificity was verified by melt curve analyses. Primer sequences were as follows: Iba-1, F:
0 , R: 5 0 -TCGGAGCGGATGAAGGTAA-3 0 ; and IL-1R1, F: 5 0 -ACCCAGTTCCTGACTTCAAG-3 0 , R: 5 0 -AGTCCCTGTACCAAAGCACT-3 0 . All primers were designed to span exon/exon boundaries and thus exclude amplification of genomic DNA. PCR amplification of cDNA was performed using the Quantitect SYBR Green PCR Kit (Qiagen, Valencia, CA, USA). Formation of PCR product was monitored in real time using the MyiQ Single-Color Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Relative gene expression was determined by taking the expression ratio of the gene of interest to b-actin.
Corticosterone enzyme-linked immunosorbent assay. To measure corticosterone levels, mice were killed by decapitation, and trunk blood was collected. Samples were centrifuged for 15 min at 4 1C, and the serum was removed. Levels of corticosterone were determined using an ELISA Kit (Assaypro, Kfar Saba, Israel).
Histological measurements
Immunohistochemistry. Animals were perfused trans-cardially with cold phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in 0.1 M PBS, and the brains were quickly removed and placed in 4% paraformaldehyde. After 24 h, the brains were placed in 30% sucrose solution in PBS and then frozen in optimal cutting temperature.
Bromodeoxyuridine (BrdU) immunofluorescent staining was performed on 8-mm frozen brain sections, fixated in 50% formamide/2Xssc (0.3 M NaCl and 0.03 M sodium citrate) for 2 h at 65 1C. After one wash with 2XSCC, sections were incubated in 2 N HCl for 30 min at 37 1C. Sections were then rinsed in 0.1 M boric acid at pH 8.5 and washed three times in PBS, following which they were incubated in 3% normal goat serum in 1% bovine serum albumin (BSA)/0.1% Triton for 30 min at room temperature and then incubated with rat monoclonal anti-BrdU antibody (1:200, AbD Serotec, Petach Tikva, Israel) for 48 h at 4 1C. Sections were then incubated with a secondary antibody (1:200 goat anti rat immunoglobulin G (IgG), conjugated to Alexa 555, Invitrogen) for 2 h at room temperature and counter-stained with DAPI (4,6-diamidino-2-phenylindole; Sigma, Israel).
In some experiments, microglia were visualized using an antibody to the microglia activation marker ionized calcium-binding adapter molecule-1 (Iba-1). Brain sections were first fixed in 2% paraformaldehyde, and after three PBS washes they were incubated overnight in 3% normal goat serum in 5% BSA with the primary antibody (rabbit anti Iba-1 1:220, Wako, Osaka, Japan) at 4 1C. Sections were then incubated with the secondary antibody (goat anti rabbit, 1:200; Invitrogen) for 1 h at room temperature (RT) and counter-stained with DAPI (Sigma, Israel).
In rats, microglia were visualized with an antibody that recognizes the cluster of differentiation molecule 11b (CD11b), a microglial surface marker in the brain. CD11b staining was conducted using the avidin-biotinhorseradish peroxidase (ABC) reaction. Briefly, sections were washed thrree times in PBS followed by incubation in a 0.3% hydrogen peroxide solution. Sections were then incubated in mouse monoclonal antisera against CD11b (1:100; BD Pharmingen, San Jose, CA, USA) overnight at 4 1C. The following day, tissue was incubated in biotinylated goat a-mouse IgG secondary antibody (1:200; Jackson ImmunoResearch, West Grove, PA, USA) at RT. Slices were next incubated in ABC (Vectastain Elite ABC kit, Vector Labs, Burlingame, CA, USA) in PBS for 1 h at RT. Next, sections were washed in phosphate buffer (without saline), and then exposed to a solution containing 3, 3 0 -diaminobenzidine, cobalt chloride, nickel ammonium sulfate, ammonium chloride and glucose oxidase in phosphate buffer. The peroxidase reaction was initiated by the addition of a glucose solution and reacted with the tissue for approximately 10 min. The reaction was terminated by washing sections in PBS. Stained tissue sections were dehydrated in a series of alcohols and defatted with Histoclear. Slides were then cover-slipped with Permount.
Caspase 3 immunofluorescent staining was performed on 50-mm frozen floating brain sections. The sections were fixed in methanol, washed three times with PBS and incubated overnight in 3% normal goat serum in 5% BSA with the primary antibody (rabbit anti Caspase-3 1:200, Cell signaling Technologies, Beverly, MA, USA) at 4 1C. Sections were then incubated with the secondary antibody (goat anti rabbit cy3, 1:200; Jackson Labs, West Grove, PA, USA) for 1 h at RT and counter-stained with DAPI (Sigma, Israel).
Apoptosis was detected and quantified using a commercially available fluorescent terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) kit, according to the manufacturer's protocol (Roche Diagnostics Corporation, Indianapolis, IN, USA). For positive control, sections were incubated with recombinant DNase I (Roche Diagnostics Corporation).
Image analysis. Images were captured using a Nikon Eclipse (Melville, NY, USA) and Olympus FV-1000 confocal microscope and camera (Tokyo, Japan). The number of GFP-labeled microglia (and in some studies the number of BrdU-labeled microglia and other cells), as well as the microglial soma area, were automatically measured at Â 10 magnification in a defined area exclusively containing the entire dentate gyrus (DG) or medial prefrontal cortex (PFC), for each slide, using Nikon Imaging Elements Software (NIS-Elements, Melville, NY, USA). Microglia processes length was measured by capturing images at Â 40 magnification and by manual tracing of the processes of four randomly selected cells/section using the NIS Elements software.
Statistical analysis
All data are presented as mean ± s.e.m. All statistical comparisons were computed using the SPSS 19.0 software and consisted of t-tests, one-way, two-way or three-way analyses of variance followed by Tukey's post hoc analyses or Bonnferoni's corrections, when appropriate.
RESULTS
Effects of chronic stress on microglia number, morphology and activation markers expression To examine the alterations in microglial status associated with stress-induced depression, we exposed a group of mice to 5 weeks of CUS, an established paradigm for producing depressivelike behavior, and assessed their depressive symptomatology as well as their microglia number and morphology, as compared with a group of control, non-stressed mice. CUS-exposed mice displayed significant decreases in sucrose preference and social exploration along with increased corticosterone levels (Supplementary Figures  S1a-c) . Surprisingly, CUS-exposed mice exhibited decreased numbers of microglia in the hippocampal DG (Figures 1a-c ) and, to a lesser extent, also in the medial PFC (Figure 1d ), but not in the somatosensory cortex (Figure 1e ). Some microglia within the DG assumed a dystrophic morphology (Figures 1f-g ), reflected by overall significant reductions in the length of microglial processes ( Figure 1h ) and in soma area (Figure 1i ). Similar effects were obtained when microglia were stained with Iba-1, verifying that these numerical and morphological alterations did not result from downregulation of CX3CR1 (Supplementary Figures. S1d-k). No apoptotic cells were found in either CUS-exposed or control mice following staining with either caspase-3 or TUNEL (data not shown), suggesting that the microglial decline occurred at an earlier stage during the exposure to CUS.
Corroborating the generality of these findings, exposure of rats to CMS resulted in significant decreases in sucrose preference (Supplementary Figure S2a Figure S2c) and, to a lesser (non-significant) extent, in the medial PFC (Supplementary Figure S2d) . In addition, CMS exposure significantly reduced the mRNA expression levels of the microglial markers CD11b and Iba-1, as well as the neuronal marker CD200, which normally keeps microglia in relative quiescence (Figure 1j ). Furthermore, in the CMS-exposed, but not in control rats, high negative correlations were obtained between the changes in sucrose preference from baseline to 5 weeks post-CMS initiation and the expression of CD11b (r ¼ À 0.771 vs 0.222, respectively, Po0.05) and Iba-1 (r ¼ À 0.437 vs 0.191, respectively, not significant). That is, lower microglial marker expression was associated with greater anhedonia.
Effects of short-term exposure to US on microglia number, morphology and activation marker expression In contrast with the findings presented above, previous studies on the effects of stress on microglial status reported activation rather than suppression of these cells. 39, 41, 48 Because these studies used shorter periods of stress exposure than the 5-weeks period used in the CUS model, we examined the microglial alterations induced by 1-4 days of US exposure. At day 2 following US initiation, the number of DG microglia was significantly increased (Figure 2a) , and the cells assumed an activated morphology (Figures 2b and  c) , characterized by increased soma area (Figure 2d ) and reduced processes length (Figure 2e ). At day 4 following US initiation, microglia number and soma size reverted to baseline, whereas the processes length remained shorter (Figures 2a, d and e) . At 24 h following the initiation of US exposure, the mRNA expression of the microglia activation markers Iba-1 and MHC-II was significantly increased, whereas the expression of the microglial CD200 receptor (CD200R), which serves to keep microglia in relative quiescence, was significantly decreased (Figure 2f ). To determine the mechanisms underlying the initial increase and subsequent decrease in microglia number, we investigated the effects of US on microglial proliferation and consequent apoptosis. Following 2 days of US exposure, but not at later time points, microglia exhibited substantial proliferation (Figures 2g-i) , whereas following 3 days of US exposure microglia exhibited a markedly increased labeling with caspase-3 (Figures 2j-k) , which is critically important for microglia activation, 55 but is also known to have a central role in the execution phase of cell apoptosis. 56 Indeed, at 4 (but not at 2) days post-US initiation, the stressed mice displayed a substantial number of TUNEL-stained apoptotic microglia (Figures 2l-m) , whereas almost no TUNEL-stained microglia were encountered in control (non-stressed) mice.
Effects of minocycline, imipramine and IL-1 signaling blockade on stress-induced dynamic microglial alterations and development of depressive symptomatology To examine the hypothesis that the initial stress-induced microglial activation is involved in the subsequent microglia decline and development of depressive behaviors, we examined the effects of pharmacological blockade of microglial activation using minocycline and genetic blockade of the microgliastimulating cytokine IL-1, using mice with transgenic overexpression of brain IL-1 receptor antagonist (IL-1raTG mice). 45 Because antidepressant drugs were previously shown to exert antiinflammatory effects, including suppression of microglial activation, 20, 57, 58 we also examined the microglial modulating effects of the tricyclic antidepressant imipramine. Minocycline administration (40 mg kg À 1 day À 1 via the drinking water, beginning 2 days before US initiation) completely reversed the increase in hippocampal microglia following 2 days of US exposure (Figure 3a) . Moreover, less caspase-3-labeled and TUNEL-stained apoptotic microglia were observed in US-exposed mice treated with minocycline (as compared with water only) at 3-4 days following the initiation of US exposure (Figure 3b ). Minocycline administration beginning 2 days before and continuing throughout the 5-weeks CUS exposure period blocked the decline in hippocampal microglia number (Figure 3c ) and completely prevented the suppressive effects of CUS on sucrose preference (Figure 3d) , with a similar trend for social exploration (Figure 3e ) and neurogenesis (Figure 3f ).
Imipramine administration (20 mg kg À 1 day À 1 via the drinking water, beginning 2 days before US initiation) completely reversed the increase in hippocampal microglia following 2 days of US exposure (Figure 3g ). Imipramine administration beginning 2 days before and continuing throughout the 5-weeks CUS exposure period blocked the CUS-induced decline in hippocampal microglia number (Figure 3h ) as well as their processes length (Figure 3i ) and soma size (Figure 3j ). The imipramine treatment also prevented the CUS-induced reductions in sucrose preference (Figure 3k ) and social exploration (Figure 3l ). Following 24 h of US exposure, the mRNA expression of IL-1b and ICE (the inflammasome-associated enzyme required for processing and activating IL-1b) did not change; however, the expression of IL-1ra was decreased and the expression of IL-1 receptor type I (IL-1RI) was increased (Figure 3m) , suggesting an overall increase in IL-1 signaling. This increase is functionally important, because after 2 days of US exposure WT mice displayed an increase in the number of DG microglia, whereas IL-1raTG mice showed no change in microglia number (Figure 3n) . Furthermore, acute intra-hippocampal administration of IL-1b in WT mice mimicked the effects of short-term US on microglia number and morphology (Supplementary Figure S3) . In contrast with the effects of short-term US, exposure to CMS in rats significantly decreased the mRNA expression of ICE but had no effect on the expression of IL-1b, IL-1ra and IL-1R, representing an overall decreased IL-1 signaling (Figure 3o) . The impaired IL-1 signaling in IL-1raTG mice was associated with a complete blockade of the CUS-induced decrease in hippocampal microglia number .05 for treatment (before vs after treatment) effect). *Po0.05 compared with Control non-stressed mice. **Po0.05 compared with CUS-exposed saline-injected mice and with LPS-injected control mice. ***Po0.05 compared with CUS-exposed saline-injected mice. þ Po0.05 compared with both Control nonstressed mice and with CUS-exposed mice treated with granulocyte-macrophage colony-stimulating factor (GM-CSF). þþ Po0.05 compared with the corresponding Control non-stressed mice either before or after drug treatment.
# Po0.05 compared with the corresponding water-or minocycline-drinking CUS-exposed mice after drug treatment.
w Po0.05 compared with the corresponding 'Before drug' condition. (Figure 3p) , as well as the suppression of sucrose preference ( Figure 3q ) and social exploration (Figure 3r ).
Effects of microglia stimulation in chronically stressed ('depressedlike') mice on depressive-like symptoms and neurogenesis To provide direct causal evidence for the involvement of microglia depletion in CUS-induced depressive-like symptoms and suppressed neurogenesis, we examined the possible anti-depressive effects of microglia stimulation in CUS-exposed mice, using two of the most well-characterized microglia activators-LPS (endotoxin) and M-CSF. 59 In the first experiment, following verification that CUS exposure produced the expected decreases in sucrose consumption and social exploration, the control and CUSexposed mice were acutely administrated with either LPS (100 mg kg À 1 , i.p.) or saline. Four to 5 h later, their behavior was assessed in the Porsolt forced swim test (an established test for depressive-like behavior in rodents), as well as the open field, social exploration and sucrose preference tests (the latter was conducted 24 h post injections). Whereas in control (non-stressed) mice LPS increased floating time (Figure 4a ) and decreased the latency to first float (Figure 4b ), in CUS-exposed mice it produced the opposite effects, completely reversing the depression/despairlike behaviors. Similarly, LPS administration reduced locomotor activity (Supplementary Figure S4a) in the open field test and the time spent in the center of the field (considered a measure of anxiety) (Supplementary Figure S4b) in control mice, whereas in CUS-exposed mice LPS increased locomotor activity and the time spent in the center of the filed, reversing the suppressive effects of CUS on these parameters. LPS administration did not significantly reverse the CUS-induced decreases in sucrose preference (Supplementary Figure  S4c ) and social exploration (Supplementary Figure S4d) . LPS administration produced an overall increase in DG microglia number, completely normalizing the CUS-induced reduction in microglia number (Figure 4c) . Finally, whereas in control mice LPS produced a small decrease in the generation of BrdU-labeled (new) DG cells, in CUS-exposed mice it caused a dramatic increase in cell generation, completely reversing the CUS-induced suppression of this process (Figure 4d ).
In the second experiment, following verification that CUS exposure produced the expected decreases in sucrose consumption and social exploration, the control and CUS-exposed mice were injected daily (i.p.) with either M-CSF (100 mg kg À 1 ) or saline for 5 days. Following the fifth injection, saline-treated CUS-exposed mice displayed elevated floating time in the Porsolt forced swim test, and this effect was reversed by M-CSF (Figure 4e) . A similar pattern of results was obtained with respect to the latency to first float, but this finding did not reach statistical significance (Figure 4f ). Treatment with M-CSF, but not saline, also completely reversed the suppressive effects of CUS on sucrose preference (Figure 4g ) and social exploration (Figure 4h ). M-CSF administration produced an overall increase in DG microglia number, completely normalizing microglia number in CUSexposed mice (Figure 4i) , as well as an overall increase in microglia proliferation (Figure 4j) . Furthermore, CUS-exposed mice injected with M-CSF also displayed a marked increase in the generation of new (BrdU-labeled) DG cells that are not microglia (Figure 4k) .
In a third experiment, we tested the effects of imipramine and minocycline (which, as shown above, produce anti-depressive effects when administered throughout the CUS exposure period) in CUS-exposed mice (that is, when the mice already exhibited depressive-like symptoms). GM-CSF, which is known to induce microglial activation, 50, 51 was used as a positive control. Following verification that CUS exposure produced the expected decreases in sucrose consumption and social exploration, animals were treated with the drugs for 2 weeks (imipramine and minocycline were administered continuously via the drinking water and GM-CSF was injected i.p. three times per week). The various treatments produced differential effects on DG microglia number (Figure 4l ), reflected by a significant group difference. Specifically, whereas both water and minocycline-drinking CUS-exposed mice displayed significant reductions in DG microglia numbers (as compared with control non-stressed mice), imipramine-treated mice displayed no differences from any of the groups, whereas GM-CSF-treated CUS-exposed mice displayed significantly greater number of microglia as compared with the control CUS-exposed mice (Figure 4l) . Water-and minocycline-drinking CUS-exposed mice displayed significantly elevated floating time in the Porsolt forced swim test, whereas imipramine and GM-CSF-treated mice showed no difference from non-stressed controls (Figure 4m) . A similar pattern of results was obtained with respect to the latency to first float, but this finding did not reach statistical significance (Figure 4n ). Treatment with GM-CSF, but not minocycline or imipramine, completely reversed the suppressive effects of CUS on sucrose preference (Figure 4o ). In the social exploration test, all the CUS-exposed groups displayed reduced exploration time before the treatment, and further reductions were evident during the 2-weeks drug administration period in the water-, minocycline-and imipramine-treated animals. In contrast, treatment with GM-CSF induced an elevation (albeit not statistically significant) in the social exploration time (Figure 4p ).
DISCUSSION
The results indicate that chronic stress produces dynamic, bi-directional alterations in microglial status, including an initial phase of proliferation and activation followed by apoptosis, dystrophy and decline. The effects of chronic stress were at least partly selective to the hippocampus, suggesting that microglia decline contributes, probably along with reductions in neurogenesis, neuronal elements and astrocyte numbers, to the known decreases in the volume of this structure in depressed humans. 60, 61 The results further demonstrate that stimulation of microglia in CUS-exposed mice reversed their depressive-like neuro-behavioral symptomatology, providing the first direct causal evidence that disturbances in microglial functioning has an etiological role in psychopathology, in general, and in major depression, in particular ( Figure 5) .
The finding that a relatively short-term exposure to US results in microglia proliferation and activation is consistent with previous studies, demonstrating that exposure to acute tail-shock stress results in hippocampal microglia activation 35 and repeated daily restraint for 4-21 days produces increased microglial number and activated morphology in hippocampus and PFC. 39, 41, 48 The results further suggest that the US-induced microglial proliferation and activation depend on signaling via the IL-1 receptor, as they did not occur in mice with transgenic overexpression of IL-1ra. Furthermore, the results suggest that the initial US-induced microglial activation was responsible for the subsequent microglial apoptosis and decline, as well as the development of depressive symptomatology and suppressed neurogenesis, because all of these effects were also prevented by minocycline or IL-1ra overexpression (as shown here and in previous reports 42, 43 ), whereas minocycline administration to mice with established CUS-induced depressive-like behavior had no beneficial effect. Similarly to the effects of minocycline, the antidepressive effects of imipramine also seem to depend, at least partly, on suppression of the initial microglial activation and the subsequent microglial decline, consistently with the known acute anti-inflammatory effects of antidepressant drugs, because imipramine administration to mice with established CUS-induced depressive-like behavior produced minimal beneficial effects.
The finding that stress-induced proliferation and activation was followed by microglial apoptosis corroborates the results of a previous study demonstrating the same phenomenon using flow cytometric methodology, 39 although no apoptosis was found in other studies on the effects of repeated restraint stress on microglial status. 41, 47 Interestingly, the apoptosis-related molecule caspase-3, 56 which in the present study was found to be elevated 3 days post-US initiation, has recently been shown to be critically involved in regulating microglial activation (consistently with other indices of microglial activation at this time, see Figure 2 ). Caspase-3 elevation was shown to lead to microglial apoptosis in some studies 62 but not in others. 55 Similar inconsistent findings also characterize the effects of various chronic stress procedures on inflammatory cytokines, with some studies reporting elevated brain cytokine levels, 63 other studies reporting deceased levels 64 and yet additional studies reporting no effects of chronic stressors on inflammatory cytokines levels. [65] [66] [67] Together with the results of the present study, these findings suggest that various stress procedures produce either activation or decline of microglia number and functioning, as well as dynamic transitions between activation and decline, possibly depending on various parameters of the stress paradigm (for example, type, severity, duration/ chronicity) and other variables such as the subjects' genetics and environmental conditions. Based on the finding that the microglial decline occurred at a later phase of stress exposure than did microglial activation, it may be suggested that in humans microglial decline accounts for depression associated with chronic stressors such as poverty, medical disabilities or lasting marital discord, which are indeed associated more strongly with depressive symptomatology than are acute stressors, such as specific negative life events. 31, 32 Over the past decade, it has become evident that microglia are not merely idle cells, waiting to be activated by injury or infection, but rather are active and motile in their 'quiescent' state, interacting with neurons and other cellular components, and participating in physiological processes, such as synaptic formation and pruning. 7, 8 These findings are consistent with the emerging notion that immune-like processes have an important modulatory role in brain and behavioral functioning. 68, 69 However, despite the evolving literature on the physiological role of 'quiescent' microglia, there is almost no data on their direct contribution to the regulation of behavioral/psychological processes. The findings of the present study provide one of the first direct demonstrations that suppression of microglial activation status and reduction in their number can produce detrimental neuro-behavioral effects, in contrast with previous neurological and psychiatric literature, which implicated only microglial activation in neuropathology and psychopathology. Although the data presented here do not directly address the mechanism(s) relating microglial decline and depression, several lines of evidence suggest that chronic stress-induced microglial decline induces depressive-like behavior, at least partly, via its detrimental effects on mechanisms related to neural plasticity and neurogenesis, whose suppression has been implicated in the pathogenesis of depression. 70 These lines of evidence include: (1) Microglia and the inflammatory cytokines that they secrete have a critical physiological role in hippocampal-related neural and behavioral plasticity as well as in neurogenesis; 8, 24, 68 (2) In many physiological or neuro-pathological conditions, microglia express and secrete neurotrophic substances, such as IGF-1 (insulin-like growth factor 1) and brain-derived neutrotrophic factor (BDNF); [71] [72] [73] [74] and (3) Microglia stimulation with either LPS or M-CSF produce dramatic beneficial effects on hippocampal cytogenesis in chronically stressed animals (Figures 4d and k) . Interestingly, M-CSF and GM-CSF were previously found to induce microglial production of IGF-1 following cerebral ischemia 59 and BDNF during recovery in a model of spinal cord injury. 75 The finding that under certain chronic stress conditions the depressive-like syndrome is associated with microglial decline, rather than activation, may be related to several inconsistencies in the inflammatory hypothesis of depression, including findings that: (1) In many studies, depressed patients were reported to have normal or even reduced levels of inflammatory markers 12, 13 (for example, a recent study reported that lower levels of CSF IL-6, IL-8 and tumor necrosis factor-a are associated with current depression and lower CSF IL-6 levels predict future depression during a follow-up of almost two decades 76 ); (2) Anti-depressants often provide clinical relief without attenuating pro-inflammatory markers; 77 (3) Serotonin-specific reuptake inhibitors (SSRIs) can sometimes increase rather than decrease the production of proinflammatory cytokines; 78 (4) Non-steroidal anti-inflammatory drugs (NSAIDs) do not always influence depression severity (for example, 79 ) and can even attenuate the anti-depressant effects of SSRIs; 78, 80 consistently, in either rodents or humans, NSAID administration blocks the early anti-depressant effects induced by implantation of deep-brain-stimulation electrodes in the subgenual cingulated gyrus, that is, these effects depend on the pro-inflammatory (possibly microglia stimulating) effect of this procedure and occur even without any current delivery; 81 and (5) Treatment with the anti-inflammatory drug infliximab produces anti-depressant effects in depressed patients with high baseline inflammatory biomarkers but exacerbates symptoms in patients with low levels of inflammation. 82 Together with the evidence for the role of inflammation in depression, 14, 19, 83 these findings suggest that at least under certain conditions deviation of microglia from their homeostatic state (that is, microglia activation following exposure to various immune challenges or relatively short-term stressors, as well as microglia suppression following chronic stress) can trigger the development of depression.
Administration of LPS to CUS-exposed mice, which increased hippocampal microglia number to normal levels, partially reversed the depressive-like behavioral symptoms and suppressed neurogenesis. Interestingly, in accordance with previous studies 17, 18 LPS produced the opposite effects, that is, depressive-like behavior and suppressed neurogenesis in non-stressed mice, emphasizing Figure 5 . A model representing the dynamic alterations in microglia status as a function of repeated stress exposure. An initial period of stress-induced interleukin (IL)-1-dependent microglial proliferation and activation leads to subsequent microglial apoptosis, decline in numbers and assumption of dystrophic morphology, which are causally related to the development of depressive symptomatology and suppressed neurogenesis. The model suggests that depression cannot be treated unitarily. Indeed, effective anti-depressive procedures should take the inflammatory/microglial status into account, and depending on whether these cells are activated or suppressed, either microglia-suppressive agents (for example, minocycline, IL-1 signaling blockers) or microglia-activating drugs (for example, macrophage colony-stimulating factor, granulocytemacrophage colony-stimulating factor should be used.
the importance of studying the properties of anti-depressive procedures using a chronic model of depression. The fact that LPS only partially reversed the CUS-induced depressive-like effects, despite completely reversing the effects of CUS on microglia and neurogenesis, may be related to the acute nature of this experiment, considering that LPS was injected only once and behavioral measurements were taken several hours before the animals were killed (allowing more time for LPS to produce its effects on microglia and neurogenesis). In any case, the partial antidepressive effects of LPS in CUS-exposed mice corroborate and explain the findings of a previous clinical study demonstrating a beneficial, anti-depressive effect of LPS in severely depressed patients. 84 M-CSF can be more translationally relevant than LPS, because it did not cause depressive symptoms in non-stressed mice, and it completely reversed the depressive symptoms after a few days of treatment. GM-CSF (also termed sargramostim) may be also translationally relevant, because it has been marketed under the trade names Leukine (Genzyme) and Leucomax (Novartis) for more than two decades, mainly for replenishment of white blood cells following chemotherapy, acceleration of white blood cell recovery following autologous bone marrow transplantation. Thus, M-CSF, its derivatives and related molecules (for example, IL-34), as well as GM-CSF and other microglia stimulators, can serve as fastacting anti-depressants, specifically in patients with major depression and stress-related disorders who exhibit normal or low levels of inflammatory markers.
